FindTrial
Sign In

PD1 Inhibitor

DRUG6 trials

Sponsors

Roswell Park Cancer Institute, Fred Hutchinson Cancer Center, Jacobio Pharmaceuticals Co., Ltd., The First Affiliated Hospital of Zhengzhou University, Yanhong Deng

Conditions

Advanced Solid TumorAnatomic Stage IV Breast Cancer AJCC v8ChemotherapyColon CancerCryoballoon AblationEsophageal Squamous Cell CarcinomaGastric CancerGlutathione

Phase 1

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
TerminatedNCT04639245
Fred Hutchinson Cancer CenterAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm +3
Start: 2021-07-19End: 2022-08-16Updated: 2023-08-03
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
CompletedNCT04721223
Jacobio Pharmaceuticals Co., Ltd.Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma +1
Start: 2021-04-26End: 2023-12-29Updated: 2024-09-19
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
RecruitingNCT06896422
The First Affiliated Hospital of Zhengzhou UniversityChemotherapy, Glutathione, Non-Small Cell Lung Cancer +1
Start: 2025-06-01End: 2027-12-31Target: 80Updated: 2025-08-07

Phase 2

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
TerminatedNCT04093323
Roswell Park Cancer InstituteHLA-A2 Positive Cells Present, Refractory Melanoma
Start: 2024-11-13End: 2025-06-19Updated: 2026-02-25
A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
Not yet recruitingNCT06957977
Zhongguang Luo, MDCryoballoon Ablation, Gastric Cancer
Start: 2025-05-01End: 2027-05-01Target: 42Updated: 2025-05-06

Unknown Phase

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
CompletedNCT06900686
Yanhong DengColon Cancer, Rectal Cancer
Start: 2013-03-20End: 2025-03-23Updated: 2025-03-28

Related Papers

A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands.
2026-01-03
Systemic Infusion of dsRNA (Rintatolimod) plus IFNa Selectively Enhances Intratumoral CTL Influx in Cancer Patients 2701
The Journal of Immunology2025-11-01
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
Journal for ImmunoTherapy of Cancer2024-07-0122 citations
Attamage-A1: Phase I/II study of autologous CD8+ and CD4+ transgenic t cells expressing high affinity MAGE-A1-specific T-cell receptor (TCR) combined with anti-PD(L)1 in patients with metastatic MAGE-A1 expressing cancer.
Journal of Clinical Oncology2022-02-166 citations
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
Journal for ImmunoTherapy of Cancer2021-11-0150 citations